VJHemOnc

Official Registration to EBMT 2026 Sign up to attend the 52nd Annual Meeting of the EBMT in-person in Madrid or virtually. Get the best rate by registering before the Early Bird deadline on 19 January 2026.

Want to find out about the latest updates and advances in transplantation and cellular therapy?🩸

Then you won't want to miss the 52nd Annual Meeting of the EBMT taking place 22–25 March in Madrid, Spain, & online.🇪🇸💻

Register here:
➡️ buff.ly/0fBo0ka

#EBMT26 #HemOnc #BMTsm @theebmt.bsky.social

Just one week to go until #CART26 kicks off in Palma de Mallorca, Spain, and online!🇪🇸 💻

Hear from the meeting chair, Annalisa Ruggeri, who encourages you to register for this hybrid meeting:
🎥 buff.ly/poXdp9x

Register here:
➡️ buff.ly/LMXQ0qU..

#CARTCell #ImmunoOnc #HemOnc @theebmt.bsky.social

Have you registered for #CART26 yet?🩸

Hear from @alexrampotas.bsky.social, who highlights the importance of the meeting as a platform for exchanging ideas & showcasing new data in the field of CAR-T & cellular therapy:

🎥 buff.ly/WhO2pQl

Register here:
👉 buff.ly/NBpWzCH

@theebmt.bsky.social

Want to find out about the latest advances in #CARTCell therapy?🩸💉

Register for the EBMT-EHA 8th European CAR T-cell Meeting taking place next month, and stay tuned for our exclusive coverage of this fantastic event!🎥

Click here to register:
👉 buff.ly/kVxJ8jg.. 👈

#CART26 @theebmt.bsky.social

We are thrilled to be the official media partner for the annual EBMT-EHA European CAR T-cell Meeting, taking place in Palma de Mallorca, Spain, from 12–14 February! 🇪🇸

Want to join us there or attend virtually?

Register here:
👉 buff.ly/HFpKa82..

#CARTCell #CART26 @theebmt.bsky.social

In an interview from #iwCLL2025, Nicolas Martinez-Calle provides insight into the UNCOVER project, which aims to evaluate inequalities in the diagnosis and survival of patients with CLL in England.

Watch here:

👉 buff.ly/FZdouqO 👈

#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky

🩸🎥 Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies.

Don't miss this insightful roundtable discussion from #iwAL25 with leading experts Eunice Wang, David Sallman, Gabriel Mannis, & Andrew Wei.

Watch now: 👉 buff.ly/VJJUbmz

#AMLsm #Leusm #Leukemia

At #IMS25, we spoke with Lisa Leypoldt, who shared findings from the cytogenetic subgroup analyses of the Phase II GMMG-CONCEPT trial evaluating Isa-KRd in newly diagnosed #myeloma.

Click here to watch:

🎥 buff.ly/Ut0Ne7p

#MMSM #MultipleMyeloma #CTSM #ImmunoOnc #BloodSky #HemeSky #MedSky

Thank you to Ali Taher for speaking with us recently and providing valuable insight into the management of acute complications of #thalassemia that may present to the emergency department.

Watch the interview here:

👉 buff.ly/yL0drrc 👈

#Hematology #BloodSky #HemeSky #MedSky

🎥 Vanthana Bharathi of @mdanderson.bsky.social discusses optimizing preventive care for patients with CLL using evidence-based strategies:

👉 buff.ly/BKMPQGT 👈

#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky

In an interview from #SOHO2025, @krishpatelmd.bsky.social of @scri.com comments on the potential of NK cell-based therapies for B-cell lymphomas.

Click here to watch:

👉 buff.ly/jMYSlMT 👈

#LYMsm #Lymphoma #HemOnc #BloodSky #HemeSky #MedSky

🎥 Asya Varshavsky-Yanovsky shares insight into a study showing that a high peak in absolute lymphocyte count following cilta-cel infusion in patients with #myeloma predicts for increased risk of delayed neurological toxicities:

👉 buff.ly/MjL0Oku 👈

#CARTcell #MMSM #MultipleMyeloma #ImmunoOnc #IMS25

Recently, Gottfried von Keudell shared the long-term follow-up results from the Phase II ELM-2 study evaluating the efficacy of the bispecific antibody odronextamab in patients with R/R #FollicularLymphoma.

Watch here:

👉 buff.ly/6GUNfkY 👈

#ImmunoOnc #LYMsm #CTSM #TrialUpdate #SOHO2025 #MedSky

What are the key risk factors for the development of bone disease in patients with #thalassemia? 🩸🦴

Julian Waung provided insight into this in a recent interview – watch here:

👉 buff.ly/Oe2kknT 👈

#Hematology #BloodSky #HemeSky #MedSky

At #iwNHL25, Alexey Danilov of @cityofhope.bsky.social and Meghan Thompson of @mskcancercenter.bsky.social sat down to provide an update on BTK-targeting therapies in non-Hodgkin #lymphoma and CLL.🩸

This is a discussion you don't want to miss!

Click here:
🎥 buff.ly/t3TZTiT

#LYMsm #HemOnc

The IMPROVE trial compared the impact of paused versus continuous BTKi therapy during vaccination in patients with CLL.🩸💉

We recently had the pleasure of speaking to Helen Parry to find out more about the study:

🎥 buff.ly/j1K0VV8

#CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc

Check out this fantastic discussion with #lymphoma experts Martin Dreyling & Georg Hess, who discuss key advances in MCL treatment. Topics covered:

🔸 The TRIANGLE trial
🔸 The role of novel agents
🔸 Treatment approaches for frontline and relapsed disease

👉 buff.ly/QbNZjR2

#LymSM #HemOnc

🎥 Mazyar Shadman of @fredhutch.org presents the results of a post hoc analysis & MAIC comparing the outcomes of fit patients treated with zanubrutinib in the SEQUOIA trial to the outcomes of patients treated with AV in AMPLIFY:

👉 buff.ly/paPH5vx 👈

#CLLsm #iwCLL2025 #Leusm #CTSM #BloodSky #HemeSky

It was fantastic to catch up with @jmikhaelmd.bsky.social at #SOHO2025 to gain insight into areas of consensus & controversy in the current & future management of R/R #MultipleMyeloma!🩸

Watch the interview here:

👉 buff.ly/7AoA6tc 👈

#MMsm #Myeloma #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky

In an interview from #iwAL25, Tara Lin discusses the possibility of tailoring treatment for secondary AML dependent on mutational profile, highlighting the heterogeneity of this disease.

Watch here:

👉 buff.ly/HbJTfmF 👈

#AMLsm #Leusm #Leukemia #HemOnc #BloodSky

It was great to catch up with the wonderful Anna Schuh at #iwCLL2025 to hear about ongoing efforts to improve the outcomes & care of patients with CLL in resource-limited settings.

Watch the interview here:

🎥 buff.ly/sZGLLe2

#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky

We recently had the pleasure of interviewing the lovely Payal Desai to hear about several topics in the field of #SickleCellDisease, including the potential of the six-minute walk test as a prognostic tool. 🚶

Learn more here: 👉 buff.ly/iMa7wAa

#Hematology #BloodSky #HemeSky #MedSky

Want to gain insight into the use of bispecific antibodies & other immunotherapies in early lines of treatment for #NonHodgkinLymphoma?🩸

Check out our discussion from #iwNHL25, with leading experts @DocHutchings, @elizabeth_budde, Lorenzo Falchi, & Sameh Gaballa:

🎥 buff.ly/CPiM5kC

#LYMsm #HemOnc

In a recent interview, Jesús San Miguel comments on the updated findings of the Phase III GEM2017FIT trial, which evaluated the efficacy of DaraKRd versus KRd in patients with newly diagnosed #MultipleMyeloma.

Click to watch:

👉 buff.ly/RVZjPoG 👈

#CTSM #TrialUpdate #IMS25 #MMsm #Myeloma #BloodSky

What should the optimal pre-transfusion hemoglobin target be in patients with thalassemia? 🤔🩸

We caught up with Maria Domenica Cappellini recently to find out!

Click here to watch the interview:

🎥 👉 buff.ly/B8HDjTL

#Thalassemia #Hematology #BloodSky #HemeSky #MedSky

#iwAL25 | John DiPersio comments on the challenges of treating T-cell malignancies with bispecific antibody therapy, and shares insights into the development of WU-CART-007, an anti-CD7 allogeneic CAR T-cell product:

🎥 buff.ly/s2zXiCa

#ALLsm #Leusm #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky

It was fantastic to catch up with the lovely Meral Beksac at #IMS25 to hear about strategies for improving CAR T-cell responsiveness and overcoming resistance in patients with #MultipleMyeloma.

Watch the interview here:

🎥 buff.ly/Rm44VmO

#MMsm #Myeloma #CARTCell #ImmunoOnc #BloodSky #HemeSky

How should physicians approach the management of patients with CLL who relapse following treatment with a triplet regimen? 💭🩸

Jacob Soumerai discussed this in a recent interview:

🎥 buff.ly/6qCplqB

#CLLsm #Leusm #iwCLL2025 #HemOnc #BloodSky #HemeSky #MedSky

At #SOHO2025, Asfand Yar Cheema of @clevelandclinic.bsky.social stopped by to share insights into the clinical outcomes of patients with #PolycythemiaVera or MDS treated with GLP-1 agonists.

Click here to watch the interview:

👉 buff.ly/KcqIbrj 👈

#MDSsm #MPNsm #HemOnc #BloodSky #HemeSky #MedSky

In an interview from #IMS25, Doris Hansen of @moffittnews.bsky.social outlined the results from a CIBMTR study assessing the safety and efficacy of cilta-cel in R/R #MultipleMyeloma.💉🩸

Watch here:

👉 buff.ly/fMxLmKd 👈

#IMS25 #MMsm #Myeloma #ImmunoOnc #CARTCell @myeloma-society.bsky.social